|
Diagnostic performance of HA in the validation set. |
||||||
| HA cut-off |
Sensitivity (%) |
Specificity (%) |
NPV (%) |
PPV (%) |
Population involved (%) |
Interpretation |
|
|
||||||
| <16 |
91 |
36 |
82 |
55 |
24 |
Absence of fibrosis (F0F1) (82% certainty) |
| >121 |
14 |
99 |
57 |
94 |
7 |
Presence of fibrosis (F2) (94% certainty) |
| ≤ 25 |
78 |
53 |
89 |
34 |
46 |
Absence of severe fibrosis (F0F1F2) (89% certainty) |
| >160 |
22 |
100 |
81 |
100 |
5 |
Presence of severe fibrosis (F3) (100% certainty) |
| ≤ 50 |
100 |
79 |
100 |
20 |
75 |
Absence of cirrhosis (F0F1F2F3) (100% certainty) |
| >237 |
31 |
99 |
96 |
57 |
3 |
Presence of cirrhosis (F4) (57% certainty) |
|
Note 1: Accuracy = Sensitivity + Specificity + NPV + PPV. Note 2: Population involved stands for the proportion of patients who fall in the corresponding cut-off. | ||||||
Halfon et al. Comparative Hepatology 2005 4:6 doi:10.1186/1476-5926-4-6 |
||||||